Global Companion Diagnostics for Oncology Market Insights, Forecast to 2029
This report presents an overview of global market for Companion Diagnostics for Oncology market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Companion Diagnostics for Oncology, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Companion Diagnostics for Oncology, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Companion Diagnostics for Oncology revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Companion Diagnostics for Oncology market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Companion Diagnostics for Oncology revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Agilent Technologies, Illumina, Roche, BioMйrieux, Foundation Medicine, ArcherDX, Qiagen, Thermo Fisher Scientific and Amoy Diagnostics, etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Companion Diagnostics for Oncology in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Companion Diagnostics for Oncology companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Companion Diagnostics for Oncology revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Companion Diagnostics for Oncology, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Companion Diagnostics for Oncology, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Companion Diagnostics for Oncology revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Companion Diagnostics for Oncology market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Companion Diagnostics for Oncology revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Agilent Technologies, Illumina, Roche, BioMйrieux, Foundation Medicine, ArcherDX, Qiagen, Thermo Fisher Scientific and Amoy Diagnostics, etc.
By Company
- Agilent Technologies
- Illumina
- Roche
- BioMйrieux
- Foundation Medicine
- ArcherDX
- Qiagen
- Thermo Fisher Scientific
- Amoy Diagnostics
- Abbott
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Laboratories
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Companion Diagnostics for Oncology in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Companion Diagnostics for Oncology companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Companion Diagnostics for Oncology revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next-Generation Sequencing (NGS)
1.3 Market by Application
1.3.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Contract Research Organizations
1.3.4 Laboratories
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Companion Diagnostics for Oncology Market Perspective (2018-2029)
2.2 Global Companion Diagnostics for Oncology Growth Trends by Region
2.2.1 Companion Diagnostics for Oncology Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Companion Diagnostics for Oncology Historic Market Size by Region (2018-2023)
2.2.3 Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029)
2.3 Companion Diagnostics for Oncology Market Dynamics
2.3.1 Companion Diagnostics for Oncology Industry Trends
2.3.2 Companion Diagnostics for Oncology Market Drivers
2.3.3 Companion Diagnostics for Oncology Market Challenges
2.3.4 Companion Diagnostics for Oncology Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Companion Diagnostics for Oncology by Players
3.1.1 Global Companion Diagnostics for Oncology Revenue by Players (2018-2023)
3.1.2 Global Companion Diagnostics for Oncology Revenue Market Share by Players (2018-2023)
3.2 Global Companion Diagnostics for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Companion Diagnostics for Oncology, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Companion Diagnostics for Oncology Market Concentration Ratio
3.4.1 Global Companion Diagnostics for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Diagnostics for Oncology Revenue in 2022
3.5 Global Key Players of Companion Diagnostics for Oncology Head office and Area Served
3.6 Global Key Players of Companion Diagnostics for Oncology, Product and Application
3.7 Global Key Players of Companion Diagnostics for Oncology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY TYPE
4.1 Global Companion Diagnostics for Oncology Historic Market Size by Type (2018-2023)
4.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029)
5 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY APPLICATION
5.1 Global Companion Diagnostics for Oncology Historic Market Size by Application (2018-2023)
5.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Companion Diagnostics for Oncology Market Size (2018-2029)
6.2 North America Companion Diagnostics for Oncology Market Size by Type
6.2.1 North America Companion Diagnostics for Oncology Market Size by Type (2018-2023)
6.2.2 North America Companion Diagnostics for Oncology Market Size by Type (2024-2029)
6.2.3 North America Companion Diagnostics for Oncology Market Share by Type (2018-2029)
6.3 North America Companion Diagnostics for Oncology Market Size by Application
6.3.1 North America Companion Diagnostics for Oncology Market Size by Application (2018-2023)
6.3.2 North America Companion Diagnostics for Oncology Market Size by Application (2024-2029)
6.3.3 North America Companion Diagnostics for Oncology Market Share by Application (2018-2029)
6.4 North America Companion Diagnostics for Oncology Market Size by Country
6.4.1 North America Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Companion Diagnostics for Oncology Market Size by Country (2018-2023)
6.4.3 North America Companion Diagnostics for Oncology Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Companion Diagnostics for Oncology Market Size (2018-2029)
7.2 Europe Companion Diagnostics for Oncology Market Size by Type
7.2.1 Europe Companion Diagnostics for Oncology Market Size by Type (2018-2023)
7.2.2 Europe Companion Diagnostics for Oncology Market Size by Type (2024-2029)
7.2.3 Europe Companion Diagnostics for Oncology Market Share by Type (2018-2029)
7.3 Europe Companion Diagnostics for Oncology Market Size by Application
7.3.1 Europe Companion Diagnostics for Oncology Market Size by Application (2018-2023)
7.3.2 Europe Companion Diagnostics for Oncology Market Size by Application (2024-2029)
7.3.3 Europe Companion Diagnostics for Oncology Market Share by Application (2018-2029)
7.4 Europe Companion Diagnostics for Oncology Market Size by Country
7.4.1 Europe Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023)
7.4.3 Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Companion Diagnostics for Oncology Market Size (2018-2029)
8.2 China Companion Diagnostics for Oncology Market Size by Type
8.2.1 China Companion Diagnostics for Oncology Market Size by Type (2018-2023)
8.2.2 China Companion Diagnostics for Oncology Market Size by Type (2024-2029)
8.2.3 China Companion Diagnostics for Oncology Market Share by Type (2018-2029)
8.3 China Companion Diagnostics for Oncology Market Size by Application
8.3.1 China Companion Diagnostics for Oncology Market Size by Application (2018-2023)
8.3.2 China Companion Diagnostics for Oncology Market Size by Application (2024-2029)
8.3.3 China Companion Diagnostics for Oncology Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Companion Diagnostics for Oncology Market Size (2018-2029)
9.2 Asia Companion Diagnostics for Oncology Market Size by Type
9.2.1 Asia Companion Diagnostics for Oncology Market Size by Type (2018-2023)
9.2.2 Asia Companion Diagnostics for Oncology Market Size by Type (2024-2029)
9.2.3 Asia Companion Diagnostics for Oncology Market Share by Type (2018-2029)
9.3 Asia Companion Diagnostics for Oncology Market Size by Application
9.3.1 Asia Companion Diagnostics for Oncology Market Size by Application (2018-2023)
9.3.2 Asia Companion Diagnostics for Oncology Market Size by Application (2024-2029)
9.3.3 Asia Companion Diagnostics for Oncology Market Share by Application (2018-2029)
9.4 Asia Companion Diagnostics for Oncology Market Size by Region
9.4.1 Asia Companion Diagnostics for Oncology Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Companion Diagnostics for Oncology Market Size by Region (2018-2023)
9.4.3 Asia Companion Diagnostics for Oncology Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type
10.2.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application
10.3.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country
10.4.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Details
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Companion Diagnostics for Oncology Introduction
11.1.4 Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.1.5 Agilent Technologies Recent Developments
11.2 Illumina
11.2.1 Illumina Company Details
11.2.2 Illumina Business Overview
11.2.3 Illumina Companion Diagnostics for Oncology Introduction
11.2.4 Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.2.5 Illumina Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Companion Diagnostics for Oncology Introduction
11.3.4 Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.3.5 Roche Recent Developments
11.4 BioMйrieux
11.4.1 BioMйrieux Company Details
11.4.2 BioMйrieux Business Overview
11.4.3 BioMйrieux Companion Diagnostics for Oncology Introduction
11.4.4 BioMйrieux Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.4.5 BioMйrieux Recent Developments
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Details
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Companion Diagnostics for Oncology Introduction
11.5.4 Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.5.5 Foundation Medicine Recent Developments
11.6 ArcherDX
11.6.1 ArcherDX Company Details
11.6.2 ArcherDX Business Overview
11.6.3 ArcherDX Companion Diagnostics for Oncology Introduction
11.6.4 ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.6.5 ArcherDX Recent Developments
11.7 Qiagen
11.7.1 Qiagen Company Details
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Companion Diagnostics for Oncology Introduction
11.7.4 Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.7.5 Qiagen Recent Developments
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Introduction
11.8.4 Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.8.5 Thermo Fisher Scientific Recent Developments
11.9 Amoy Diagnostics
11.9.1 Amoy Diagnostics Company Details
11.9.2 Amoy Diagnostics Business Overview
11.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Introduction
11.9.4 Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.9.5 Amoy Diagnostics Recent Developments
11.10 Abbott
11.10.1 Abbott Company Details
11.10.2 Abbott Business Overview
11.10.3 Abbott Companion Diagnostics for Oncology Introduction
11.10.4 Abbott Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.10.5 Abbott Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next-Generation Sequencing (NGS)
1.3 Market by Application
1.3.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Contract Research Organizations
1.3.4 Laboratories
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Companion Diagnostics for Oncology Market Perspective (2018-2029)
2.2 Global Companion Diagnostics for Oncology Growth Trends by Region
2.2.1 Companion Diagnostics for Oncology Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Companion Diagnostics for Oncology Historic Market Size by Region (2018-2023)
2.2.3 Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029)
2.3 Companion Diagnostics for Oncology Market Dynamics
2.3.1 Companion Diagnostics for Oncology Industry Trends
2.3.2 Companion Diagnostics for Oncology Market Drivers
2.3.3 Companion Diagnostics for Oncology Market Challenges
2.3.4 Companion Diagnostics for Oncology Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Companion Diagnostics for Oncology by Players
3.1.1 Global Companion Diagnostics for Oncology Revenue by Players (2018-2023)
3.1.2 Global Companion Diagnostics for Oncology Revenue Market Share by Players (2018-2023)
3.2 Global Companion Diagnostics for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Companion Diagnostics for Oncology, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Companion Diagnostics for Oncology Market Concentration Ratio
3.4.1 Global Companion Diagnostics for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Diagnostics for Oncology Revenue in 2022
3.5 Global Key Players of Companion Diagnostics for Oncology Head office and Area Served
3.6 Global Key Players of Companion Diagnostics for Oncology, Product and Application
3.7 Global Key Players of Companion Diagnostics for Oncology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY TYPE
4.1 Global Companion Diagnostics for Oncology Historic Market Size by Type (2018-2023)
4.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029)
5 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY APPLICATION
5.1 Global Companion Diagnostics for Oncology Historic Market Size by Application (2018-2023)
5.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Companion Diagnostics for Oncology Market Size (2018-2029)
6.2 North America Companion Diagnostics for Oncology Market Size by Type
6.2.1 North America Companion Diagnostics for Oncology Market Size by Type (2018-2023)
6.2.2 North America Companion Diagnostics for Oncology Market Size by Type (2024-2029)
6.2.3 North America Companion Diagnostics for Oncology Market Share by Type (2018-2029)
6.3 North America Companion Diagnostics for Oncology Market Size by Application
6.3.1 North America Companion Diagnostics for Oncology Market Size by Application (2018-2023)
6.3.2 North America Companion Diagnostics for Oncology Market Size by Application (2024-2029)
6.3.3 North America Companion Diagnostics for Oncology Market Share by Application (2018-2029)
6.4 North America Companion Diagnostics for Oncology Market Size by Country
6.4.1 North America Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Companion Diagnostics for Oncology Market Size by Country (2018-2023)
6.4.3 North America Companion Diagnostics for Oncology Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Companion Diagnostics for Oncology Market Size (2018-2029)
7.2 Europe Companion Diagnostics for Oncology Market Size by Type
7.2.1 Europe Companion Diagnostics for Oncology Market Size by Type (2018-2023)
7.2.2 Europe Companion Diagnostics for Oncology Market Size by Type (2024-2029)
7.2.3 Europe Companion Diagnostics for Oncology Market Share by Type (2018-2029)
7.3 Europe Companion Diagnostics for Oncology Market Size by Application
7.3.1 Europe Companion Diagnostics for Oncology Market Size by Application (2018-2023)
7.3.2 Europe Companion Diagnostics for Oncology Market Size by Application (2024-2029)
7.3.3 Europe Companion Diagnostics for Oncology Market Share by Application (2018-2029)
7.4 Europe Companion Diagnostics for Oncology Market Size by Country
7.4.1 Europe Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023)
7.4.3 Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Companion Diagnostics for Oncology Market Size (2018-2029)
8.2 China Companion Diagnostics for Oncology Market Size by Type
8.2.1 China Companion Diagnostics for Oncology Market Size by Type (2018-2023)
8.2.2 China Companion Diagnostics for Oncology Market Size by Type (2024-2029)
8.2.3 China Companion Diagnostics for Oncology Market Share by Type (2018-2029)
8.3 China Companion Diagnostics for Oncology Market Size by Application
8.3.1 China Companion Diagnostics for Oncology Market Size by Application (2018-2023)
8.3.2 China Companion Diagnostics for Oncology Market Size by Application (2024-2029)
8.3.3 China Companion Diagnostics for Oncology Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Companion Diagnostics for Oncology Market Size (2018-2029)
9.2 Asia Companion Diagnostics for Oncology Market Size by Type
9.2.1 Asia Companion Diagnostics for Oncology Market Size by Type (2018-2023)
9.2.2 Asia Companion Diagnostics for Oncology Market Size by Type (2024-2029)
9.2.3 Asia Companion Diagnostics for Oncology Market Share by Type (2018-2029)
9.3 Asia Companion Diagnostics for Oncology Market Size by Application
9.3.1 Asia Companion Diagnostics for Oncology Market Size by Application (2018-2023)
9.3.2 Asia Companion Diagnostics for Oncology Market Size by Application (2024-2029)
9.3.3 Asia Companion Diagnostics for Oncology Market Share by Application (2018-2029)
9.4 Asia Companion Diagnostics for Oncology Market Size by Region
9.4.1 Asia Companion Diagnostics for Oncology Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Companion Diagnostics for Oncology Market Size by Region (2018-2023)
9.4.3 Asia Companion Diagnostics for Oncology Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type
10.2.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application
10.3.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country
10.4.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Details
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Companion Diagnostics for Oncology Introduction
11.1.4 Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.1.5 Agilent Technologies Recent Developments
11.2 Illumina
11.2.1 Illumina Company Details
11.2.2 Illumina Business Overview
11.2.3 Illumina Companion Diagnostics for Oncology Introduction
11.2.4 Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.2.5 Illumina Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Companion Diagnostics for Oncology Introduction
11.3.4 Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.3.5 Roche Recent Developments
11.4 BioMйrieux
11.4.1 BioMйrieux Company Details
11.4.2 BioMйrieux Business Overview
11.4.3 BioMйrieux Companion Diagnostics for Oncology Introduction
11.4.4 BioMйrieux Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.4.5 BioMйrieux Recent Developments
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Details
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Companion Diagnostics for Oncology Introduction
11.5.4 Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.5.5 Foundation Medicine Recent Developments
11.6 ArcherDX
11.6.1 ArcherDX Company Details
11.6.2 ArcherDX Business Overview
11.6.3 ArcherDX Companion Diagnostics for Oncology Introduction
11.6.4 ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.6.5 ArcherDX Recent Developments
11.7 Qiagen
11.7.1 Qiagen Company Details
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Companion Diagnostics for Oncology Introduction
11.7.4 Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.7.5 Qiagen Recent Developments
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Introduction
11.8.4 Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.8.5 Thermo Fisher Scientific Recent Developments
11.9 Amoy Diagnostics
11.9.1 Amoy Diagnostics Company Details
11.9.2 Amoy Diagnostics Business Overview
11.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Introduction
11.9.4 Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.9.5 Amoy Diagnostics Recent Developments
11.10 Abbott
11.10.1 Abbott Company Details
11.10.2 Abbott Business Overview
11.10.3 Abbott Companion Diagnostics for Oncology Introduction
11.10.4 Abbott Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.10.5 Abbott Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of Next-Generation Sequencing (NGS)
Table 4. Global Companion Diagnostics for Oncology Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Companion Diagnostics for Oncology Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Companion Diagnostics for Oncology Market Share by Region (2018-2023)
Table 8. Global Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Companion Diagnostics for Oncology Market Share by Region (2024-2029)
Table 10. Companion Diagnostics for Oncology Market Trends
Table 11. Companion Diagnostics for Oncology Market Drivers
Table 12. Companion Diagnostics for Oncology Market Challenges
Table 13. Companion Diagnostics for Oncology Market Restraints
Table 14. Global Companion Diagnostics for Oncology Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Companion Diagnostics for Oncology Revenue Share by Players (2018-2023)
Table 16. Global Top Companion Diagnostics for Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
Table 17. Global Companion Diagnostics for Oncology Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Companion Diagnostics for Oncology Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Companion Diagnostics for Oncology, Headquarters and Area Served
Table 20. Global Key Players of Companion Diagnostics for Oncology, Product and Application
Table 21. Global Key Players of Companion Diagnostics for Oncology, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2018-2023)
Table 25. Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2024-2029)
Table 27. Global Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Companion Diagnostics for Oncology Revenue Share by Application (2018-2023)
Table 29. Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Companion Diagnostics for Oncology Revenue Share by Application (2024-2029)
Table 31. North America Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Companion Diagnostics for Oncology Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Companion Diagnostics for Oncology Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Companion Diagnostics for Oncology Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Companion Diagnostics for Oncology Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 63. Agilent Technologies Company Details
Table 64. Agilent Technologies Business Overview
Table 65. Agilent Technologies Companion Diagnostics for Oncology Product
Table 66. Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 67. Agilent Technologies Recent Developments
Table 68. Illumina Company Details
Table 69. Illumina Business Overview
Table 70. Illumina Companion Diagnostics for Oncology Product
Table 71. Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 72. Illumina Recent Developments
Table 73. Roche Company Details
Table 74. Roche Business Overview
Table 75. Roche Companion Diagnostics for Oncology Product
Table 76. Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 77. Roche Recent Developments
Table 78. BioMйrieux Company Details
Table 79. BioMйrieux Business Overview
Table 80. BioMйrieux Companion Diagnostics for Oncology Product
Table 81. BioMйrieux Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 82. BioMйrieux Recent Developments
Table 83. Foundation Medicine Company Details
Table 84. Foundation Medicine Business Overview
Table 85. Foundation Medicine Companion Diagnostics for Oncology Product
Table 86. Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 87. Foundation Medicine Recent Developments
Table 88. ArcherDX Company Details
Table 89. ArcherDX Business Overview
Table 90. ArcherDX Companion Diagnostics for Oncology Product
Table 91. ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 92. ArcherDX Recent Developments
Table 93. Qiagen Company Details
Table 94. Qiagen Business Overview
Table 95. Qiagen Companion Diagnostics for Oncology Product
Table 96. Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 97. Qiagen Recent Developments
Table 98. Thermo Fisher Scientific Company Details
Table 99. Thermo Fisher Scientific Business Overview
Table 100. Thermo Fisher Scientific Companion Diagnostics for Oncology Product
Table 101. Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 102. Thermo Fisher Scientific Recent Developments
Table 103. Amoy Diagnostics Company Details
Table 104. Amoy Diagnostics Business Overview
Table 105. Amoy Diagnostics Companion Diagnostics for Oncology Product
Table 106. Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 107. Amoy Diagnostics Recent Developments
Table 108. Abbott Company Details
Table 109. Abbott Business Overview
Table 110. Abbott Companion Diagnostics for Oncology Product
Table 111. Abbott Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 112. Abbott Recent Developments
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of Next-Generation Sequencing (NGS)
Table 4. Global Companion Diagnostics for Oncology Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Companion Diagnostics for Oncology Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Companion Diagnostics for Oncology Market Share by Region (2018-2023)
Table 8. Global Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Companion Diagnostics for Oncology Market Share by Region (2024-2029)
Table 10. Companion Diagnostics for Oncology Market Trends
Table 11. Companion Diagnostics for Oncology Market Drivers
Table 12. Companion Diagnostics for Oncology Market Challenges
Table 13. Companion Diagnostics for Oncology Market Restraints
Table 14. Global Companion Diagnostics for Oncology Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Companion Diagnostics for Oncology Revenue Share by Players (2018-2023)
Table 16. Global Top Companion Diagnostics for Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
Table 17. Global Companion Diagnostics for Oncology Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Companion Diagnostics for Oncology Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Companion Diagnostics for Oncology, Headquarters and Area Served
Table 20. Global Key Players of Companion Diagnostics for Oncology, Product and Application
Table 21. Global Key Players of Companion Diagnostics for Oncology, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2018-2023)
Table 25. Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2024-2029)
Table 27. Global Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Companion Diagnostics for Oncology Revenue Share by Application (2018-2023)
Table 29. Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Companion Diagnostics for Oncology Revenue Share by Application (2024-2029)
Table 31. North America Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Companion Diagnostics for Oncology Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Companion Diagnostics for Oncology Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Companion Diagnostics for Oncology Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Companion Diagnostics for Oncology Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 63. Agilent Technologies Company Details
Table 64. Agilent Technologies Business Overview
Table 65. Agilent Technologies Companion Diagnostics for Oncology Product
Table 66. Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 67. Agilent Technologies Recent Developments
Table 68. Illumina Company Details
Table 69. Illumina Business Overview
Table 70. Illumina Companion Diagnostics for Oncology Product
Table 71. Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 72. Illumina Recent Developments
Table 73. Roche Company Details
Table 74. Roche Business Overview
Table 75. Roche Companion Diagnostics for Oncology Product
Table 76. Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 77. Roche Recent Developments
Table 78. BioMйrieux Company Details
Table 79. BioMйrieux Business Overview
Table 80. BioMйrieux Companion Diagnostics for Oncology Product
Table 81. BioMйrieux Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 82. BioMйrieux Recent Developments
Table 83. Foundation Medicine Company Details
Table 84. Foundation Medicine Business Overview
Table 85. Foundation Medicine Companion Diagnostics for Oncology Product
Table 86. Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 87. Foundation Medicine Recent Developments
Table 88. ArcherDX Company Details
Table 89. ArcherDX Business Overview
Table 90. ArcherDX Companion Diagnostics for Oncology Product
Table 91. ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 92. ArcherDX Recent Developments
Table 93. Qiagen Company Details
Table 94. Qiagen Business Overview
Table 95. Qiagen Companion Diagnostics for Oncology Product
Table 96. Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 97. Qiagen Recent Developments
Table 98. Thermo Fisher Scientific Company Details
Table 99. Thermo Fisher Scientific Business Overview
Table 100. Thermo Fisher Scientific Companion Diagnostics for Oncology Product
Table 101. Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 102. Thermo Fisher Scientific Recent Developments
Table 103. Amoy Diagnostics Company Details
Table 104. Amoy Diagnostics Business Overview
Table 105. Amoy Diagnostics Companion Diagnostics for Oncology Product
Table 106. Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 107. Amoy Diagnostics Recent Developments
Table 108. Abbott Company Details
Table 109. Abbott Business Overview
Table 110. Abbott Companion Diagnostics for Oncology Product
Table 111. Abbott Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 112. Abbott Recent Developments
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Companion Diagnostics for Oncology Market Share by Type: 2022 VS 2029
Figure 3. Polymerase Chain Reaction (PCR) Features
Figure 4. Next-Generation Sequencing (NGS) Features
Figure 5. Global Companion Diagnostics for Oncology Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Companion Diagnostics for Oncology Market Share by Application: 2022 VS 2029
Figure 7. Pharmaceutical and Biopharmaceutical Companies Case Studies
Figure 8. Contract Research Organizations Case Studies
Figure 9. Laboratories Case Studies
Figure 10. Others Case Studies
Figure 11. Companion Diagnostics for Oncology Report Years Considered
Figure 12. Global Companion Diagnostics for Oncology Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Companion Diagnostics for Oncology Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Companion Diagnostics for Oncology Market Share by Region: 2022 VS 2029
Figure 15. Global Companion Diagnostics for Oncology Market Share by Players in 2022
Figure 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Companion Diagnostics for Oncology Revenue in 2022
Figure 18. North America Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 20. North America Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 21. North America Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 22. United States Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US$ Million)
Figure 25. Europe Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 26. Europe Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 27. Europe Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 28. Germany Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. China Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US$ Million)
Figure 35. China Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 36. China Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 37. Asia Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US$ Million)
Figure 38. Asia Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 39. Asia Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 40. Asia Companion Diagnostics for Oncology Market Share by Region (2018-2029)
Figure 41. Japan Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. South Korea Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. China Taiwan Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. India Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Australia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 49. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 50. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 51. Brazil Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Mexico Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Turkey Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Israel Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. GCC Countries Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Agilent Technologies Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 58. Illumina Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 59. Roche Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 60. BioMйrieux Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 61. Foundation Medicine Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 62. ArcherDX Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 63. Qiagen Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 64. Thermo Fisher Scientific Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 65. Amoy Diagnostics Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 66. Abbott Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Figure 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Companion Diagnostics for Oncology Market Share by Type: 2022 VS 2029
Figure 3. Polymerase Chain Reaction (PCR) Features
Figure 4. Next-Generation Sequencing (NGS) Features
Figure 5. Global Companion Diagnostics for Oncology Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Companion Diagnostics for Oncology Market Share by Application: 2022 VS 2029
Figure 7. Pharmaceutical and Biopharmaceutical Companies Case Studies
Figure 8. Contract Research Organizations Case Studies
Figure 9. Laboratories Case Studies
Figure 10. Others Case Studies
Figure 11. Companion Diagnostics for Oncology Report Years Considered
Figure 12. Global Companion Diagnostics for Oncology Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Companion Diagnostics for Oncology Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Companion Diagnostics for Oncology Market Share by Region: 2022 VS 2029
Figure 15. Global Companion Diagnostics for Oncology Market Share by Players in 2022
Figure 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Companion Diagnostics for Oncology Revenue in 2022
Figure 18. North America Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 20. North America Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 21. North America Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 22. United States Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US$ Million)
Figure 25. Europe Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 26. Europe Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 27. Europe Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 28. Germany Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. China Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US$ Million)
Figure 35. China Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 36. China Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 37. Asia Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US$ Million)
Figure 38. Asia Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 39. Asia Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 40. Asia Companion Diagnostics for Oncology Market Share by Region (2018-2029)
Figure 41. Japan Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. South Korea Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. China Taiwan Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. India Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Australia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Type (2018-2029)
Figure 49. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Application (2018-2029)
Figure 50. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 51. Brazil Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Mexico Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Turkey Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Israel Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. GCC Countries Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Agilent Technologies Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 58. Illumina Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 59. Roche Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 60. BioMйrieux Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 61. Foundation Medicine Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 62. ArcherDX Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 63. Qiagen Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 64. Thermo Fisher Scientific Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 65. Amoy Diagnostics Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 66. Abbott Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
